Rationale for Immune Checkpoint Inhibitors Plus Targeted Therapy in Metastatic Melanoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Rationale for Immune Checkpoint Inhibitors Plus Targeted Therapy in Metastatic Melanoma

Published:2020-12-01 Issue:12 Volume:6 Page:1957
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Dummer Reinhard¹,Ascierto Paolo A.²,Nathan Paul³,Robert Caroline⁴,Schadendorf Dirk⁵

Affiliation:

1. University Hospital Zürich Skin Cancer Center, Zürich, Switzerland

2. Istituto Nazionale Tumori IRCCS Fondazione “G. Pascale,” Naples, Italy

3. Mount Vernon Cancer Centre, Northwood, United Kingdom

4. Gustave Roussy and Paris-Sud-Paris-Saclay University, Villejuif, France

5. University Hospital Essen, Essen, Germany, and German Cancer Consortium, Heidelberg, Germany

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Link

https://jamanetwork.com/journals/jamaoncology/articlepdf/2770701/jamaoncology_dummer_2020_rv_200008_1606943520.86467.pdf

Reference75 articles.

1. Mutations of the BRAF gene in human cancer.;Davies;Nature,2002

2. Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma.;Robert;N Engl J Med,2019

3. Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma.;Ascierto;Eur J Cancer,2020

4. Many ways to resistance: how melanoma cells evade targeted therapies.;Kozar;Biochim Biophys Acta Rev Cancer,2019

5. Universes collide: combining immunotherapy with targeted therapy for cancer.;Wargo;Cancer Discov,2014

Cited by 49 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mechanism insights and therapeutic intervention of tumor metastasis: latest developments and perspectives;Signal Transduction and Targeted Therapy;2024-08-02

2. Role of Surgery in Metastatic Melanoma and Review of Melanoma Molecular Characteristics;Cells;2024-03-07

3. First-in-human study of naporafenib (LXH254) with or without spartalizumab in adult patients with advanced solid tumors harboring MAPK signaling pathway alterations;European Journal of Cancer;2024-01

4. A signature of seven hypoxia-related lncRNAs is a potential biomarker for predicting the prognosis of melanoma;American Journal of Cancer Research;2024

5. Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies;Signal Transduction and Targeted Therapy;2023-12-18

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3